Company Overview and News
THE WOODLANDS, Texas, July 25, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) today reported net income in the second quarter of 2018 of $22.2 million, compared to net income of $18.8 million in the second quarter of 2017. Diluted earnings per share in the second quarter of 2018 was $0.29 and include total after-tax charges of $7.2 million, or $0.09 per diluted share, related to spin-off and other restructuring activities.
APY.WI DOV.WI DOV APY
Good morning and welcome to Dover's Second Quarter 2018 Earnings Conference Call. Speaking today are Richard J. Tobin, President and Chief Executive Officer; Brad Cerepak, Senior Vice President and CFO; and Paul Goldberg, Vice President of Investor Relations.
APY.WI DOV APY
The Equity and Income Fund earned 0.2% in the quarter, while the Lipper Balanced Fund Index, the Fund’s performance benchmark, gained 1.1%.
PM DOV.WI NOV TEL CVS FNF BAC CHTR APY.WI FNFV DOV GM ORCL LBRDB BAC C AAL BHGE COMM MA ARNC TWC LBRDK BHI CGBBW OCLCF JLL LBRDA FL APY UNH
THE WOODLANDS, Texas, July 05, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that it will release its second quarter 2018 operating results on Wednesday, July 25, 2018 after the market closes. The Company has scheduled a conference call for Thursday, July 26, 2018 at 8 a.m. Central Time (9 a.m. Eastern Time) to discuss the results.
THE WOODLANDS, Texas, June 08, 2018 (GLOBE NEWSWIRE) -- Apergy Corporation (“Apergy”) (NYSE:APY) announced today that Sivasankaran "Soma" Somasundaram, President and Chief Executive Officer, and Jay Nutt, Senior Vice President and Chief Financial Officer, will attend and meet with investors at the Wells Fargo 2018 West Coast Energy Conference in San Francisco, California on June 12, 2018. The presentation to be used in the investor meetings will be available on Tuesday, June 12, 2018, prior to the commencement of the meetings under the “Investors – Media Files” tab of our website at http://www.
WFC WFCNP APY.WI APY
Apergy Corp. provides technologies that help companies drill for and produce oil and gas. Its products include artificial lift equipment and solutions, rod pumping systems, electric submersible pump systems, gas lift systems, hydraulic lift and pump services, progressive cavity pumps and drive systems and plunger lift systems, and polycrystalline diamond cutters for drilling. The firm operates through two segments: Production & Automation Technologies and Drilling Technologies.
Dover Corporation (DOV - Free Report) has successfully completed the spin-off of its upstream energy businesses — Wellsite — which has been later named Apergy. Now on, Dover will be a standalone company focused on industrial products and manufacturing equipment, while Apergy will be an independent public company. Spin-off History In December 2017, Dover announced a tax-free spin-off of its upstream energy businesses within the Energy segment, which comprises Dover Artificial Lift, Dover Energy Automation, and US Synthetic.
ATLKY ATLKF ATTLF APY.WI DOV.WI GGG ATLCY DOV AIT DTK APY
THE WOODLANDS, Texas, May 09, 2018 (GLOBE NEWSWIRE) -- S&P Dow Jones Indices, a division of S&P Global Inc., announced on May 2, 2018 that Apergy Corporation (“Apergy”) (NYSE:APY), a leading provider of highly engineered equipment and technologies that help companies drill for and produce oil and gas safely and efficiently around the world, will be added to the S&P 400 MidCap index prior to the open of trading on Thursday, May 10, 2018.
2018-09-18 - Asif
Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...
2018-09-18 - Asif
Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...
2018-09-18 - Asif
Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...
as of ET